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Abstract 
Objective: T-cell Lymphoma Invasion and Metastasis 1 (Tiam1)protein is a guanine nucleotide exchange factor that activates 
proteins of the Rho family of GTPases, specifically Rac1. Expression of Tiam1 protein has been reported in various human 
cancers and has been associated with lymphangiogenesis and promotion of tumor metastasis. The objective of this study was 
to further evaluate the expression of Tiam1 in primary and metastatic colorectal cancer (CRC) and its association 
withvariousclinicopathological parameters, includinggender, age, tumor size, Dukes stage, tumor grade, lymph node status 
and original location of the primary tumor (colon versus rectum).  
Methods: The expression of Tiam1 was detected by immunohistochemistry in 200 samples of primary CRC tissues and in 
100 samples of lymph node tissue with CRC metastases.  
Results: Tiam1 was overexpressed in the majority of both primary (69,5% of the cases) and metastatic (63% of the cases) 
CRC tumor tissues. Overexpression of Tiam1 in primary CRC was statistically associated withlowertumor grade(P=0,04), 
whereas in metastatic CRC a statistically significant association between Tiam1 expression and  female gender (P=0,003), 
tumor size >5cm (P=0,001) and localization  of the primary tumor in the colon (P=0,009) was found. 
Conclusion: Overexpression of Tiam1 protein may represent a frequent event in CRC. Additional studies are warranted to 
further investigate its potential value as a marker of prognosis and treatment response in this form of cancer.  
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Introduction 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth most common cause of 
cancer-related death worldwide [1]. Although 5-year survival rates are particularly high (approximately 
80-90%) when the tumor is confined to the bowel wall and still amenable to potentially curable resection, the 
majority of patients either present with metastatic disease or go on to develop metastases relatively early in 
the course of their disease [2].  
Despite some significant advances in the treatment of advanced CRC, including the advent of 
molecularagents targeting specific signalling pathways or genetic alterations (such as the anti-EGFR 
monoclonal antibodies cetuximaband panitumumab) the overall prognosis ofthese patients remains poor. The 
development of more effective treatments for this form of cancer is, therefore, urgently needed [3]. 
Undoubtedly, it is also now increasingly recognized that CRC is a genetically heterogeneous disease and that 
an improved understanding of the key molecular mechanisms underlying its pathogenesis and progression 
carry significant prognostic and therapeutic implications in the clinical setting.  
T-cell Lymphoma Invasion and Metastasis 1 (Tiam1) protein is a guanine nucleotide exchange factor 
(GEF) that mediates the bound of a GTP molecule at the Rac1 GTPase, a member of the Rho family of 
GTPases [4-6]. Activation of the Tiam1-Rac1 signaling pathway is involved in the reorganization of the actin 
cytoskeleton [7], cell cycle progression [8], invasion [4] and metastasis [9]. According to previous 
experimental data, Tiam1 and Rac may promote the oncogenic transformation of cells [10], while 
Tiam1-deficient mice have been shown to be resistant to the growth of Ras-induced skin tumors[11]. 
Tiam1 has been previously implicated in the progression of various solid tumors other than CRC, such as 
renal cell carcinoma [12], breast cancer [13], prostate cancer [14] and hepatocellular carcinoma [15]. The 
objective of this study was to evaluate the immunohistochemical expression patterns of Tiam1 in tissue 
samples of primary and metastatic colorectal cancer, compare these patterns and explore their potential  
association with  standard clinicopathological  parameters, includinggender, age, tumor size, Dukes stage, 
tumor grade, lymph node status and original location of the primary tumor (colon versus rectum). 
Material and methods 
Patients and Tissue Samples 
This was a retrospective study of 200 cases of colorectal adenocarcinoma, diagnosed and treated in Tzaneion 
Hospital of Pireus, Greece, from 2000 to 2005. Our study population comprised 113 men and 87 women with 
a mean age of 70 years (range 29-92). The demographic information, clinical presentation and other medical 
data were extracted from the medical charts. The corresponding slides and formalin-fixed, paraffin-embedded 
tissue blocks were retrieved from the archives of the Pathology Department of our institution, and additional 
sections were obtained for the performance of immunohistochemistry.Histological diagnosis was made 
according to the criteria of the WHO classification [16] and stage was defined according to both American 
Joint Committee on Cancer (AJCC) criteria [17] and Dukes system [18]. One hundred cases were classified as 
AJCC stages IIA, IIB and IIC, which are grouped as stage B according to the Dukes system (tumor invading 
the muscularispropria of the bowel wall without spread to lymph nodes). The remaining 100 cases were 
classified as stages IIIA, IIIB and IIIC according to the AJCC criteria, corresponding to Dukes stage C (tumor 
spread to regional lymph nodes without evidence of spread to other organs).  
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Immunohistochemistry 
One paraffin-embedded tissue block for each case was selected, according to the major criteria of well 
preserved tissue morphology and quantitatively adequate material. In cases of Dukes stage C colorectal 
carcinoma one paraffin-embedded block from lymph node tissue with metastatic CRC was also selected. The 
immunohistochemical protocol for the detection of Tiam1 was carried out on 4μm-thick tissue sections of the 
corresponding blocks. A rabbit polyclonal antibody (clone sc-872, Santa Cruz Biotechnology, Inc., USA) 
against Tiam1 protein at a dilution of 1:100 was used. The marker was applied to the sections using a Bond-X 
fully automated staining system (Vision BioSystems, Newcastle upon Tyne, UK). This assay is based on a 
soluble dextran-polymer system which minimizes any background that may be caused by endogenous biotin. 
After deparaffinization and peroxidase blocking, antigen retrieval was performed with Bond ER1 buffer. 
Sections were incubated firstly with primary antibody for 60 min at room temperature and then with 
horseradish peroxidase labeled polymer for 30 minutes. The antigen-antibody reaction was visualized using 
diaminobenzidinetetrahydrochloride (DAB) as a chromogen substrate. The sections were counterstained with 
Mayer’s hematoxylin (for 30 sec), dehydrated and mounted. Omission of the primary antibody in 
simultaneously incubated sections was used as a negative control.  
Evaluation of immunohistochemical staining 
Evaluation of the immunostained slides was performed by two independent pathologists who were blinded to 
the clinicopathological data. In cases of disagreement between the two observers, the slides were reviewed by 
a third (senior) pathologist and a consensus evaluation was made.  
The expression of Tiam1 was considered as positive only in the presence of a cytoplasmic staining pattern 
of tumor cells. Tiam1 expression was evaluated as negative when no staining or staining in <10% neoplastic 
cells was observed. Weak staining in >10% neoplastic cells was considered as 1+ positive, moderate staining 
in >10% neoplastic cells as 2+ positive and strong staining in >10% neoplastic cells as 3+ positive, as 
previously described [19]. 
Statistical analysis 
The correlation of Tiam1 expression with various clinicopathological parameters, includinggender, age, tumor 
size, Dukes stage, tumor grade, lymph node status and original location of the primary tumor (colon versus 
rectum) was determined using the Chi-square test. A two-tailed P-value ≤0,05 was considered to be 
statistically significant. The statistical analysis was performed with the use of the SPSS software 16.0 for 
Windows (SPSS Inc, Chicago, IL, USA). 
Results 
The associations between Tiam-1 expression inprimary CRC and the clinicopathologic parameters evaluated 
are summarized in Table 1, along with the results of Chi-square analysis for each studied variable. Tiam-1 
positive staining was detected in 69,5% (139/200) of all primary CRC cases. More specifically, a positive 
staining for Tiam1 was observed in 73% of Dukes stage B cases and in 66% of Dukes stage C cases. The 
positive staining was evaluated as weak in 51,1% of CRC cases (Figure 1), moderate in 33,1% (Figure 2) and 
strong in 15,8% of CRC cases (Figure 3). We observed that in all cases of weak positive staining, the 
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percentage of tumor cells expressing the Tiam1 protein didn’t exceed 40%, while in cases exhibiting moderate 
or strong intensity of staining that percentage was always >50%. The Chi-square test revealed no significant 
relationship between Tiam1 expression in the primary tumor and the clinicopathologic parameters examined, 
except for a correlation between positive staining and tumor differentiation (p=0,04). 
Tiam1 positive staining was observed in 63/100 (63%) lymph node tissue specimens with metastatic CRC. 
Among cases with positive staining, a weak staining  was observed  in 60,3% of cases and moderate in 
39,7% of cases. Signals of Tiam1 in both primary and metastatic colon cancer tissue were detected in the 
cytoplasm of tumor cells but not or seldom in the surrounding normal intestinal or lymph node tissue. Table 2 
shows the relationship between the expression of Tiam1 inlymph node tissue specimens with metastatic CRC 
and clinicopathological characteristics, along with the results of the Chi-square test. Tiam1 expression was 
correlated with female gender (p=0,003), tumor size>5cm (p=0,001) and localization of the primary tumor  
in the colon versus the sigmoid colon or the rectum (p=0,009). 
 
Table 1 Results of x2 analysis showing the correlations between Tiam1 expression in primary colorectal tumor specimens and 
several clinicopathological parameters 
 
Features 
Tiam1 expression (%) 
P value 
Negative Positive 
Gender 
Male 
Female 
33/113 (29,2%) 80/113 (70,8%) 
0,720 
28/87 (32,2%) 59/87 (67,8%) 
Age (years) 
≤65 
>65 
19/62 (30,6%) 43/62 (69,4%) 
0,976 
42/138 (30,4%) 96/138 (69,6%) 
Tumor size (cm in diameter) 
≤5 
>5 
38/131 (29%) 93/131 (71%) 
0,528 
23/69 (33,3%) 46/69 (66,7%) 
Dukes stage 
B 
C 
27/100 (27%) 73/100 (73%) 
0,282 
34/100 (34%) 66/100 (66%) 
Number of regional lymph nodes with metastases 
1-4  
>4  
22/70 (31,4%) 48/70 (68,6%) 
0,978 
12/30 (40%) 18/30 (60%) 
Tumor localization 
Right colon 
Left colon 
Sigmoid colon/rectum 
15/46 (32,6%) 31/46 (67,4%) 
0,970 8/28 (28,6%) 20/28 (71,4%) 
38/126 (30,2%) 88/126 (69,8%) 
Tumor grade 
Low 
Moderate 
High  
0/8 (0%) 8/8 (100%) 
0,04 51/171 (29,8%) 120/171 (70,2%) 
10/21 (47,6%) 11/21 (52,4%) 
 
When evaluatingthe expression of Tiam1in the primary and metastatic tumor sites among 
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patientsdiagnosed with Dukes stage C disease, double positivity for Tiam1 was observed  in 45% of cases, 
while in 18% of  cases positive staining was observed only in metastatic CRC specimens. Twenty one out of 
100 cases (21%) showed expression of Tiam1 protein only in the primary tumor and not in the metastatic sites, 
while in 16/100 cases (16%) negative staining was observed both in primary and in metastatic CRC 
specimens.  
 
 
Figure 1 Weakly positive immunostaining  for Tiam1 in the cytoplasm of CRC cells. 
 
Figure 2 Moderately positive immunostaining for Tiam1 in the cytoplasm of CRC cells 
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Figure 3 Strongly positive immunostaining for Tiam1 in the cytoplasm of CRC cells. 
 
Table 2 Results of x2 analysis showing the correlations between Tiam1 expression in lymph node specimens with metastatic CRC 
and several clinicopathological parameters 
 
Features 
Tiam1 expression (%) 
P value 
Negative Positive 
Gender 
Male 
Female 
29/59 (49,2%) 30/59 (50,8%) 
0,003 
8/41 (19,5%) 33/41 (80,5%) 
Age (years) 
≤65 
>65 
9/27 (33,3%) 18/27 (66,7%) 
0,644 
28/73 (38,4%) 45/73 (61,6%) 
Tumor size (cm in diameter) 
≤5 
>5 
26/68 (38,2%) 42/68 (61,8%) 
0,001 
11/32 (34,4%) 21/32 (65,6%) 
Astler – Collerstage 
C1 
C2 
31/70 (44,3%) 39/70 (55,7%) 
0,259 
6/30 (20%) 24/30 (80%) 
Tumor localization 
Right and left colon 
Sigmoid colon/rectum 
10/44 (22,7%) 34/44 (77,3%) 
0,009 
27/56 (48,2%) 29/56 (51,8%) 
Tumor grade 
Moderate 
High  
32/84 (38,1%) 52/84 (61,9%) 
0,603 
5/16 (31,2%) 11/16 (68,8%) 
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Discussion 
Tiam1 is an invasion-inducing gene, initially identified using proviral tagging in combination with in vitro 
section for invasiveness [9]. The expression and prognostic significance of Tiam1 protein has been previously 
evaluated in a variety of solid tumors, and most of these reported findings suggest that overexpression of this 
biomarker may be associated with increased disease aggressiveness and an overall adverse prognosis. Liu et 
al. [20] suggested that Tiam1 may play a causal role in the proliferation, invasion and metastasis of colorectal 
cancer and that RNAi-mediated silencing of Tiam1 may provide an opportunity to develop a new treatment 
strategy for colorectal cancer. Engerset al.[14] found that Tiam1 is significantly overexpressed in prostate 
carcinomas and in almost all preneoplastic high grade prostatic intraepithelium lesions, suggesting that altered 
expression of this biomarker may represent an early event in the development and evolution of prostate cancer. 
Most importantly, a statistically significant association between Tiam1 overexpression and a reduced 
disease-free survival, both in univariate and in multivariate analysis, was also observed in the latter study, 
indicating that Tiam1 expression may independently predict disease recurrence for these patients. In line with 
these findings, Ding et al.[15] reported that Tiam1 overexpression may predict a worse prognosis in 
hepatocellular carcinoma, while Zhao et al.[12] similarly concluded that increased Tiam1 expression may be 
associated with lymph node metastasis and reduced survival in renal cell carcinoma.  
In the present study we investigated the immunohistochemical expression of Tiam1 in tissue sections from 
primary CRC, as well as in tissue sections from lymph nodes with metastatic CRC. According to our findings, 
an increased expression of Tiam1 may be observed in the majority of tissue sections with either primary or 
metastatic colorectal adenocarcinomas. Furthermore, in the majority of CRC patients with Tiam1 
overexpression and a positive lymph node status, an increased expression of Tiam1 was detected in both the 
primary and metastatic sites, while in a smaller subset of these cases Tiam1 overexpression was observed only 
in tissue sections with metastatic CRCbut not in the primary tumor.  
The key molecular mechanisms determining the role of Tiam1 as apromoter of invasion and metastasis in 
CRC remain poorly explored. A significant role of the Wnt/β-catenin signaling pathway in colon cancer 
development has been previously suggested [21,22]. Furthermore, previous experimental data have identified 
Tiam1 as a Wnt-responsive gene that is upregulated in mouse intestinal tumors and human colon adenomas, 
while Tiam1 deficiency has been shown to significantly reduce the formation and growth of intestinal polyps 
in vivo.[21]. As previously emphasized, given the oncogenic potentials of Tiam1 and its downstream target 
Rac, it is conceivable that a cross-talk between Wnt/β-catenin and Tiam1-Rac signaling may play a major role 
in the development and progression of cancer [14].  
Furthermore, as previously reported by Minardet al.[23] Tiam1 increases colon carcinoma growth at 
metastatic sites, therefore, overexpression of Tiam1 may potentially contribute to the acquisition of the 
metastatic phenotype by colon cancer cells. Other studies have also suggested that Tiam1 overexpression may 
promote lymphangiogenesis in CRC by interaction with VEGF-C expression through the NFκB pathway [24].  
In conclusion, the results of our study suggest that overexpression of Tiam1 protein may represent a frequent 
event in CRC, and may be observed both in primary and metastatic tumors. Additional prospective studies are 
warranted in order to determine whether Tiam1 may potentially serve as a biomarker of disease progression, 
overall prognosis and treatment response in CRC patients. An improved understanding of the molecular 
mechanisms underlying the progression of CRC to the invasive and metastatic stages will greatly contribute 
to developing more effective individualized treatment strategies for this disease.  
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